top
Please input keywords
Order
*Country
한국
미국
일본
중국
영국
호주
프랑스
독일
이탈리아
싱가포르
인도
러시아
캐나다
스위스
기타 국가
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hPD-1/hTIGIT mice
Strain Name
C57BL/6-Pdcd1tm1(PDCD1)Bcgen Tigittm1(TIGIT)Bcgen/Bcgen
Common Name  B-hPD-1/hTIGIT mice
Background C57BL/6 Catalog number  120523
Related Genes 
PD-1 (Programmed death-1) ;
TIGIT
(T-cell immunoreceptor with Ig and ITIM domains)
NCBI Gene ID
18566,100043314

Protein expression analysis

from clipboard


Strain specific analysis of TIGIT and PD-1 gene expression in WT and B-hPD-1/hTIGIT mice by RT-PCR. Mouse Tigit and Pd-1 mRNA were detectable in splenocytes of wild-type (+/+) mice. Human TIGIT and PD-1 mRNA were detectable in B-hPD-1/hTIGIT homozygous mice . 




Strain specific TIGIT and PD-1 expression analysis in homozygous B-hPD-1/hTIGIT mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/hTIGIT mice (H/H) mice stimulated with anti-CD3ε in vivo (7.5 μg/mice), and analyzed by flow cytometry with species-specific anti-TIGIT antibody. Mouse TIGIT and PD-1 were exclusively detected in WT mice. Human TIGIT and PD-1 were exclusively detected in homozygous B-hPD-1/hTIGIT mice but not WT mice.


Combination therapy of hTIGIT Ab(Tiragolumab (in house)) and PD-1 Ab(pembrolizumab) 


from clipboard

Antitumor activity of anti-hTIGIT antibody Tiragolumab (in house) combined with anti-hPD-1 antibody pembrolizumab in B-hPD-1/hTIGIT mice. (A) Anti-hTIGIT antibody Tiragolumab (in house) combined with anti-hPD-1 antibody pembrolizumab inhibited MC38 tumor growth in B-hPD-1/hTIGIT mice. Murine colon cancer MC38 cells (5×105) were subcutaneously implanted into homozygous B-hPD-1/hTIGIT mice (female, 5-8 week-old, n=6). Mice were grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with anti-hTIGIT antibody Tiragolumab (in house) combined with anti-hPD-1 antibody pembrolizumab with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of anti-hTIGIT and anti-hPD-1 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hTIGIT mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hTIGIT antibodies and hPD-1 antibodies . Values are expressed as mean ± SEM.